Podcast appearances and mentions of keith flaherty

Engineering firm Hallam-ICS has sustained growth over the last decade, crediting honest company culture, inbound marketing in niche service areas, and evolving brand messaging as the reason for their success. We talk to the president and CEO, Keith Flaherty on the latest episode of Content Marketing, Engineered.TREW Marketing has worked with engineering firm Hallam-ICS for more than 7 years and over that time many of the marketing strategies and brand messaging have evolved to reflect the company's growth. We invited president and CEO Keith Flaherty to discuss the company's history, culture, and growth over the years. One thing that's truly special about Hallam-ICS is the company culture, it plays a huge role in recruiting and retaining employees and the messaging reflects this differentiator. Hallam-ICS is also seen rapid growth in niche expertise areas, such as toxic gas monitoring and arc flash, and Keith credits executive buy-in of inbound marketing as the reason they've grown and generated millions of dollars in leads in those areas.We also discuss how messaging changes with growth, and how to blend "small and friendly" messaging with "large and expert" messaging and how to stay consistent as more regional locations are added to the company.TakeawaysCompany culture is a key differentiator in attracting and retaining employees. Achieve rapid growth in niche expertise areas by leveraging inbound marketing to generate leads.Messaging should be evolved over time to blend an original small, friendly culture with the current larger, more capable image.Opening new offices requires careful selection of leaders who understand the company's culture and can effectively communicate its messaging.ResourcesConnect with Keith on LinkedInConnect with Morgan on LinkedInLearn more about Hallam-ICSCase Study: Hallam-ICS Uses Culture as a Key Differentiator in Technical SolutionsRelated Content: 4 Questions to Ask to Define Your Brand Differentiators Related Service: System Integrators

On this episode of Investor Connect, Hall T. Martin welcomes Ronan O'Hagan, President & CEO of Bectas Therapeutics Inc., a groundbreaking biotech company focused on revolutionizing precision oncology. Based in [City, State/Country], Bectas Therapeutics is committed to developing cancer therapies that target over 400,000 patients annually who do not benefit from the existing standard-of-care treatments. Ronan O'Hagan boasts over two decades of experience in building biotech teams and businesses, contributing to the development of more than 20 Investigational New Drugs (INDs) and four approved drugs. As the President & CEO of Bectas Therapeutics, O'Hagan leads a team with a mission to provide personalized cancer therapies, increasing the probability of success by fivefold and significantly reducing both cost and time in clinical development. The Bectas advisory board includes luminaries such as Dr. James Allison, a Nobel Laureate for his work in immune oncology, and Dr. Keith Flaherty, a serial entrepreneur in precision oncology. Bectas Therapeutics Inc. focuses on developing cancer therapies tailored for patients who do not benefit from existing standard treatments, a population exceeding 400,000 individuals annually. Their precision approach ensures each patient receives the right drug for their specific cancer, significantly improving the chances of success and reducing costs and time in clinical development. Ronan discusses the company's precision cancer therapies, leveraging human patient data. Bectas aims to bring Best-In-Class therapies with a unique blood-based biomarker, promising rapid value creation and potential early exits for investors. O'Hagan emphasizes the significance of clinical proof of concept and highlights the company's mission-driven approach to cancer health equity. Connect with Ronan O'Hagan and Bectas Therapeutics: LinkedIn: ; Twitter: @ohaganr   _______________________________________________________ For more episodes from Investor Connect, please visit the site at:    Check out our other podcasts here:   For Investors check out:   For Startups check out:   For eGuides check out:   For upcoming Events, check out    For Feedback please contact info@tencapital.group    Please , share, and leave a review. Music courtesy of .

View the Show Notes Page for This Episode Become a Member to Receive Exclusive Content Sign Up to Receive Peter's Weekly Newsletter Keith Flaherty is the director of clinical research at the Massachusetts General Hospital Cancer Center and a previous guest on The Drive. In this episode, Keith first delves into the statistics on cancer's prevalence as we age, underscoring the significance of finding effective treatments and early detection methodologies. He touches on the history of cancer therapeutics and illuminates the notable enhancements in cancer therapy within the last decade that are setting the stage for a promising future. He goes into detail on the potential of immunotherapy and therapies that can combat cancer's evasive tactics while explaining some of the existing challenges around specificity, cost, and scalability. Additionally, Keith highlights the significant leap in early detection methodologies, namely liquid biopsies, which have the potential not only to determine if a cancer is present in an early stage, but also identify the possible tissue of origin. We discuss: Keith's interest and expertise in cancer [3:15]; Cancer deaths by decade of life, and how cancer compares to other top causes of death [7:00]; The relationship between hormones and cancer [12:00]; The link between obesity and cancer [18:45]; Current state of treatments for metastatic cancer and reasons for the lack of progress over the decades [22:30]; The interplay between the immune system and cancer cells [32:00]; Different ways cancer can suppress the immune response, and how immunotherapy can combat cancer's evasive tactics [39:30]; Elimination of a substantial portion of cancers through immune cell engineering faces challenges of specificity, cost, and scalability [52:15]; Why TIL therapy isn't always effective, and the necessity for multimodal therapy to address various aspects of the cancer microenvironment [1:01:00]; Potential developments in cancer therapy over the next five years: T-cell activation, metabolic interventions, targeting tumor microenvironments, and more [1:06:30]; The challenge of treating metastatic cancer underscores the importance of early detection to improve survivability [1:19:15]; Liquid biopsies for early detection of cancer and determining the possible tissue of origin [1:24:45]; Commercially available cancer screening tests [1:33:45]; How to address the disparity in cancer care, and the exciting pace of progress for cancer detection and treatment [1:40:15]; and More. Connect With Peter on Twitter, Instagram, Facebook and YouTube

Joined by Dr. Keith Flaherty from Harvard Cancer Center to discuss the following topics. Dr. Flaherty background Molecular understanding of cancer & its impact on cancer types Screening/early detection Assistance of AI What is within patient's control? Impact on families, faith, worldview DR. FLAHERTY EDUCATIONAL TITLES Professor, Medicine, Harvard Medical School Director of Henri and Belinda Termeer Center for Targeted Therapy, Cancer Center, Massachusetts General Hospital Director of Clinical Research, Cancer Center, Massachusetts General Hospital Intersecting Ideas Social Platforms

Synopsis: Keith Flaherty is the Director of Clinical Research at Mass General Cancer Center and a Professor of Medicine at Harvard Medical School. Dr. Flaherty is a medical oncologist and has worked in the field for 22 years, during which he has founded seven biotech companies. He joins Rahul for an in-depth conversation about his work in oncology. They cover a wide range of topics including his early decision in school to switch from neuroscience to oncology, his entrepreneurial journey and what he's learned along the way, his perspective on the immuno-oncology landscape and opportunities that lie ahead in this field, what he values in a board and how you can be most effective as a board member, and much more. Biography: Dr. Keith Flaherty is the Director of Clinical Research at Mass General Cancer Center, a Professor of Medicine at Harvard Medical School, and an Associate Physician of Medicine, Hematology/Oncology at Massachusetts General Hospital. Dr. Flaherty is also the Deputy Chair for Biomarker Sciences and the Chair of the Developmental Therapeutics Committee in the Eastern Cooperative Oncology Group. Dr. Flaherty has served as Principal Investigator for numerous first-in-human clinical trials with novel, targeted therapies, including the first in-human trials of the first prospectively developed selective BRAF inhibitors for metastatic melanoma and has published more than 300 peer-reviewed papers. He currently serves on the board of directors of Scorpion Therapeutics (founder), Strata Oncology (founder), Kinnate Biopharma, and Clovis Oncology. Dr. Flaherty has a Bachelor of Science from Yale University and medical degree from Johns Hopkins University. Dr. Flaherty trained in internal medicine at Brigham and Women's Hospital and completed a medical oncology fellowship at the University of Pennsylvania.

For episode 2, we chat with Dr. Keith Flaherty, Founder at Scorpion Therapeutics and Director of Clinical Research at Mass General Cancer Center.First In Human is a biotech-focused podcast that interviews industry leaders and investors to learn about their journey to in-human clinical trials. Presented by Vial, a tech-enabled CRO. Episodes launch weekly on Tuesdays.To view the full episode transcript, click here.

Melanoma used to be really scary! Leading cancer researcher Keith Flaherty tells us how melanoma is actually becoming easier to treat. Keith has been working in cancer research for over 22 years, from UPenn to Mass General and Harvard Medical School. He has been one of the pioneers of immunotherapies specifically related to melanoma. In this episode, Keith and Sanjay talk about the different types of immunotherapies, why melanoma used to be so life-threatening, and how the newest treatments coming out could really change the way patients and doctors approach melanoma and cancer as a whole.

In this episode, Keith Flaherty, director of clinical research and targeted cancer therapy at Massachusetts General Hospital, shares his vast wealth of knowledge in cancer starting with the history of treatment from chemotherapy to radiation to surgical therapy and where those methodologies seemed to have leveled off. He also walks us through the timeline of advancements (and lack there of) from when the War on Cancer was declared in the 1970s, through the sequencing of the entire human genome, and all the way to today. Keith dives into the topic of immunotherapy, probably the most exciting recent development in cancer therapy, and also provides us a rundown of his notion of a different approach to cancer that attacks all the essential pillars of cancer growth and survival. Finally, we talk a little bit about liquid biopsies, we discuss the roles of CRISPR and other potentially over-hyped therapies with respect to cancer. We also touch on stem cell therapy a bit, as well as some other common cancer-related questions such as the role of vitamin D and sun exposure in melanoma, and much more. We discuss: Growing up around medicine, and finding a career that you love [7:30]; Medicine as a career, limitations of the med school teaching approach, and the dynamic and accelerating field of medicine and technology [16:30]; Explaining chemotherapy, radiation, and how a cancer develops [23:45]; Surgical oncology, cure rate of solid tumors, and survival rate after tumor removal  [33:15]; 25 years after the War on Cancer is declared, gene sequencing, and why Keith’s was fascinated by the HIV case study [37:15]; Cancer immunotherapy: History, how it works, and why some cancers respond and others don’t [46:00]; MHC complexes, and cancer cloaking mechanisms [56:00]; Comparative biology of cancer: Why some cancer can evade immune detection better than others [1:03:00]; What we learned from the Cancer Genome Atlas Project [1:07:00]; Defining targeted therapy, HER2 breast cancer, chronic leukemia, and the translocation of chromosomes [1:12:00]; Tumor protein P53, the most famous tumor suppressor gene and its ubiquity in cancer [1:17:45]; Activated oncogenes, the RAS pathway, PI3 kinase, RAF gene, and Keith’s “aha moment” [1:24:15]; Advice for starting your career as a scientist/clinician [1:37:00]; Fusion-driven cancers, targeted therapy, and the Bcr-Abl/chronic myelogenous leukemia case study [1:39:45]; Targeted therapy for fusion-driven solid tumors, adjuvant systemic therapy, and the HER2 breast cancer example [1:53:00]; Advancing melanoma treatment, survival, and cure rates with BRAF-MEK combo therapy [1:59:15]; The fundamental pillars of cancer growth and survival, and the toolkit we need to attack cancer from all angles [2:02:40]; Peter’s clinical framework for thinking about cancer and how Keith might improve it, and how the biotech environment is hampering our ability to put together novel cancer treatments [2:05:00]; How useful is CRISPR in terms of tumor suppressing? [2:16:15]; Liquid biopsies as a therapeutic monitoring tool [2:18:00]; Stem cell therapy: The efficacy and potential risks [2:25:15]; Aging and cancer: Is cancer inevitable? [2:28:45]; Vitamin D supplements, sun exposure, melanoma, and exercise [2:32:30]; How and why Keith has straddled the line between science/research and industry/drug companies, and the importance of getting more voices of practitioners at the table [2:42:00]; and More. Learn more at www.PeterAttiaMD.com Connect with Peter on Facebook | Twitter | Instagram.

I'm talking to Jess and Keith Flaherty on Book Talk Radio Club. Jess and Keith Flaherty are one of those married couples sitcoms never get right. They have been together for over twenty years and still can’t get enough of each other’s company. So much so that they wrote and published a fantasy novel together! Always Darkest published in June 2017 recently won Book Talk Radio Club's Best in Fantasy award. You cn find out more about Jess and Keith at https://www.booktalkradio.info/jessica-flaherty

I'm talking to Jess and Keith Flaherty on Book Talk Radio Club. Jess and Keith Flaherty are one of those married couples sitcoms never get right. They have been together for over twenty years and still can’t get enough of each other’s company. So much so that they wrote and published a fantasy novel together! Always Darkest published in June 2017 recently won Book Talk Radio Club's Best in Fantasy award. You cn find out more about Jess and Keith at https://www.booktalkradio.info/jessica-flaherty

I'm talking to husband and wife author team Jessica and Keith Flaherty on Book Talk Radio Club about their book Always Darkest, a novel in the Fantasy genre. They say in the film business never work with animals or kids. Let's find out what it is like to write and publish a book with one's spouse! Find out more about Jessica and Keith Flaherty and where to purchase Always Darkest at https://www.booktalkradio.info/jessica-flaherty

I'm talking to husband and wife author team Jessica and Keith Flaherty on Book Talk Radio Club about their book Always Darkest, a novel in the Fantasy genre. They say in the film business never work with animals or kids. Let's find out what it is like to write and publish a book with one's spouse! Find out more about Jessica and Keith Flaherty and where to purchase Always Darkest at https://www.booktalkradio.info/jessica-flaherty

Dr Keith Flaherty talks with ecancer at the 2013 European Cancer Congress in Amsterdam about a study that compared the progression free survival and overall survival in melanoma clinical trials with trametinib, ipilimumab and vemurafenib. The relationship between PFS and OS was established by looking at the hazard ratio reported in each of the studies and a series of sensativity analysis.

Dr Michele Maio talks with ecancer at the 2013 European Cancer Congress in Amsterdam about the survival analysis of a phase III study of ipilimumab and dacarbazine in metastatic melanoma The results of this study, with 5 years of follow up, continue to demonstrate a long-term survival benefit for patients treated with ipilimumab plus DTIC compared to placebo plus DTIC. Consistent with the results of phase II studies, survival rates appear to plateau beginning at 3 years. Dr Keith Flaherty provides additional commentary on the study